Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 |
| Revenues | 0.0 | 40.7 | 0.0 | 26.9 | 0.0 | 11.4 |
| Revenue growth | | 51.2% | | | -100.0% | |
| Cost of goods sold | 0.0 | 67.9 | 0.0 | 45.6 | 0.0 | 17.6 |
| Gross profit | 0.0 | -27.2 | 0.0 | -18.7 | 0.0 | -6.3 |
| Gross margin | | -66.8% | | -69.6% | | -55.2% |
| Research and development | 40.7 | | 26.9 | | 17.6 | |
| General and administrative | 27.2 | 27.2 | 18.7 | 18.7 | 7.7 | 6.3 |
| EBIT | -66.8 | -67.9 | -44.1 | -45.6 | -26.8 | -17.6 |
| EBIT margin | | -166.8% | | -169.6% | | -155.2% |
| Pre-tax income | -65.6 | -65.6 | -45.5 | -45.5 | -24.9 | -17.5 |
| Income taxes | 0.0 | 1.1 | 0.0 | 1.5 | 0.0 | 0.0 |
| Tax rate | 0.0% | | 0.0% | | 0.1% | 0.0% |
| Net income | -66.7 | -66.7 | -47.0 | -47.0 | -26.4 | 0.0 |
| Net margin | | -163.8% | | -174.7% | | 0.0% |
| |
| Diluted EPS | ($2.09) | ($2.09) | ($1.84) | ($1.84) | ($1.52) | |
| Shares outstanding (diluted) | 31.8 | 31.8 | 25.5 | 25.5 | 17.4 | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|